Harbour BioMed was approved to start a China Phase II trial of its anti-FcRn (batoclimab) candidate in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). CIDP is a chronic disease characterized by progressive weakness and impaired sensory function in the legs and arms. Currently, the condition is treated by corticosteroid pulses and intravenous immunoglobulin (IVIg), but these therapies cause side effects and IVIg is not always available. HBM is headquartered in the Boston area, with discovery operations in Rotterdam and labs in Suzhou . More details.... Stock Symbol: (HK: 02142) Share this with colleagues: // //